Abhilash Venugopalan

List of Publications by Year
in descending order

14	442	933447 10	1199594 12
papers	citations	h-index	g-index

15	15	15	1126
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	APOBEC Mutagenesis and Copy-Number Alterations Are Drivers of Proteogenomic Tumor Evolution and Heterogeneity in Metastatic Thoracic Tumors. Cell Reports, 2019, 26, 2651-2666.e6.	6.4	92
2	Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer. Cell Reports Medicine, 2020, 1, 100007.	6.5	78
3	Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptorâ€“Driven Lung Adenocarcinoma. Cancer Discovery, 2015, 5, 534-549.	9.4	57
4	A proteogenomic approach to map the proteome of an unsequenced pathogen â€“ Leishmania donovani. Proteomics, 2012, 12, 832-844.	2.2	42
5	Identifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics. Proteomics, 2015, 15, 340-355.	2.2	42
6	Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response. Molecular and Cellular Proteomics, 2017, 16, 891-910.	3.8	42
7	EGFR-targeted therapy results in dramatic early lung tumor regression accompanied by imaging response and immune infiltration in EGFR mutant transgenic mouse models. Oncotarget, 2016, 7, 54137-54156.	1.8	27
8	Genomic profiling of multiple sequentially acquired tumor metastatic sites from an â€œexceptional responderâ€•lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response. Journal of Physical Education and Sports Management, 2016, 2, a001263.	1.2	18
9	Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors. Molecular Cancer Therapeutics, 2022, 21, 1195-1206.	4.1	18
10	Quantitative Mass Spectrometry to Interrogate Proteomic Heterogeneity in Metastatic Lung Adenocarcinoma and Validate a Novel Somatic Mutation CDK12-G879V. Molecular and Cellular Proteomics, 2019, 18, 622-641.	3.8	15
11	SCAMP3 is a mutant EGFR phosphorylation target and a tumor suppressor in lung adenocarcinoma. Oncogene, 2021, 40, 3331-3346.	5.9	6
12	Alterations in HLA Class I-Presented Immunopeptidome and Class I-Interactome upon Osimertinib Resistance in EGFR Mutant Lung Adenocarcinoma. Cancers, 2021, 13, 4977.	3.7	5
13	Abstract 2927: Proteogenomic heterogeneity in metastatic lung adenocarcinoma revealed from rapid/warm autopsy. , 2017, , .		0
14	Abstract 4528: Quantitative mass spectrometry to interrogate proteomic heterogeneity in metastatic lung adenocarcinoma and validate a novel somatic mutation CDK12-G879V. , 2019, , .		0